Cargando…

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer

Cancer cells release DNA fragments into plasma as circulating free DNA (cfDNA). However, quantitative measurement of tumor‐derived DNA in cfDNA remains challenge. The purpose of this study was to quantitatively assess tumor‐derived DNA in lung cancer patients. By optimizing competitive allele‐specif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Wenwei, Yang, Yang, Zhang, Longzhen, Yin, Jianxin, Huang, Jingwei, Huang, Lei, Gu, Hua, Jiang, Gening, Fang, Jianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430107/ https://www.ncbi.nlm.nih.gov/pubmed/28382702 http://dx.doi.org/10.1002/cam4.980

Ejemplares similares

High mutation burden of circulating cell‐free DNA in early‐stage breast cancer patients is associated with a poor relapse‐free survival
por: Kujala, Jouni, et al.
Publicado: (2020)

Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA
por: Zuo, Zhigang, et al.
Publicado: (2020)

Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery
por: Katopodis, Periklis, et al.
Publicado: (2021)

The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta‐analysis
por: Xie, Wenli, et al.
Publicado: (2019)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)

Detection of mutations in circulating cell‐free DNA in relation to disease stage in colorectal cancer
por: Liebs, Sandra, et al.
Publicado: (2019)

Circulating lncRNA DANCR as a potential auxillary biomarker for the diagnosis and prognostic prediction of colorectal cancer
por: Shen, Xianjuan, et al.
Publicado: (2020)

Age‐stratified reference intervals unlock the clinical potential of circulating cell‐free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer
por: Ørntoft, Mai‐Britt Worm, et al.
Publicado: (2020)

Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas
por: Dhayat, Sameer A., et al.
Publicado: (2020)

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
por: Ianza, Anna, et al.
Publicado: (2021)

Methylation status and long‐fragment cell‐free DNA are prognostic biomarkers for gastric cancer
por: Ko, Kazuhide, et al.
Publicado: (2021)

Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia
por: Watts, Eleanor L., et al.
Publicado: (2022)

The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk
por: MacKintosh, Michelle L., et al.
Publicado: (2018)

Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection
por: Gutteridge, Alice, et al.
Publicado: (2017)

Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma
por: Chen, Junhui, et al.
Publicado: (2021)

MicroRNA-21 as a diagnostic and prognostic biomarker of lung cancer: a systematic review and meta-analysis
por: Wang, Wei, et al.
Publicado: (2022)

Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
por: Black, Elizabeth M., et al.
Publicado: (2022)

Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma
por: Wang, Dong, et al.
Publicado: (2020)

Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
por: Huang, Ao, et al.
Publicado: (2016)

Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta‐analysis
por: Zhang, Ziying, et al.
Publicado: (2019)

Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma
por: Liu, Yin-Qiao, et al.
Publicado: (2022)

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022)

The Potential of Circulating Cell-Free DNA Methylation as an Epilepsy Biomarker
por: Martins-Ferreira, Ricardo, et al.
Publicado: (2022)

Germline INDELs and CNVs in a cohort of colorectal cancer patients: their characteristics, associations with relapse‐free survival time, and potential time‐varying effects on the risk of relapse
por: Werdyani, Salem, et al.
Publicado: (2017)

Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer
por: Corradetti, Michael N., et al.
Publicado: (2019)

Circulating proteins and risk of pancreatic cancer: a case-subcohort study among Chinese adults
por: Kartsonaki, Christiana, et al.
Publicado: (2022)

Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers
por: Olkhov-Mitsel, Ekaterina, et al.
Publicado: (2012)

Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer
por: Gumulec, Jaromir, et al.
Publicado: (2018)

In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma
por: Yang, Man, et al.
Publicado: (2019)

Subgrouping by gene expression profiles to improve relapse risk prediction in paediatric B‐precursor acute lymphoblastic leukaemia
por: Huang, Qingsheng, et al.
Publicado: (2021)

Circulating microRNA biomarkers for lung cancer detection in Western populations
por: Yu, Haixin, et al.
Publicado: (2018)

Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression
por: Wang, Ying‐Yi, et al.
Publicado: (2020)

Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
por: Rizzuto, Ivana, et al.
Publicado: (2015)

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorization
por: Renaud, Gabriel, et al.
Publicado: (2022)

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
por: Ai, Bo, et al.
Publicado: (2016)

Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
por: Chu, Ling-Yu, et al.
Publicado: (2021)

miR-152/TNS1 axis inhibits non-small cell lung cancer progression through Akt/mTOR/RhoA pathway
por: Duan, Jinjin, et al.
Publicado: (2021)

Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse
por: Mittelstadt, Suzana, et al.
Publicado: (2023)

Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma
por: Su, Yan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hu9hfms2tk9fri4l22fiqpi9kp